Ionis Pharmaceuticals Inc (IONS)
39.13
+0.67
(+1.74%)
USD |
NASDAQ |
Nov 08, 10:50
Ionis Pharmaceuticals Revenue (TTM): 803.07M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 803.07M |
| June 30, 2024 | 813.46M |
| March 31, 2024 | 776.62M |
| December 31, 2023 | 787.65M |
| September 30, 2023 | 615.03M |
| June 30, 2023 | 630.59M |
| March 31, 2023 | 575.97M |
| December 31, 2022 | 587.37M |
| September 30, 2022 | 875.48M |
| June 30, 2022 | 848.81M |
| March 31, 2022 | 840.77M |
| December 31, 2021 | 810.46M |
| September 30, 2021 | 660.73M |
| June 30, 2021 | 687.72M |
| March 31, 2021 | 707.50M |
| December 31, 2020 | 729.26M |
| September 30, 2020 | 932.66M |
| June 30, 2020 | 940.48M |
| March 31, 2020 | 958.75M |
| December 31, 2019 | 1.123B |
| September 30, 2019 | 821.03M |
| June 30, 2019 | 798.54M |
| March 31, 2019 | 752.47M |
| December 31, 2018 | 599.68M |
| September 30, 2018 | 575.35M |
| Date | Value |
|---|---|
| June 30, 2018 | 548.27M |
| March 31, 2018 | 542.80M |
| December 31, 2017 | 514.18M |
| September 30, 2017 | 532.89M |
| June 30, 2017 | 525.50M |
| March 31, 2017 | 451.70M |
| December 31, 2016 | 372.78M |
| September 30, 2016 | 237.84M |
| June 30, 2016 | 176.04M |
| March 31, 2016 | 257.99M |
| December 31, 2015 | 283.70M |
| September 30, 2015 | 316.99M |
| June 30, 2015 | 311.94M |
| March 31, 2015 | 248.58M |
| December 31, 2014 | 214.16M |
| September 30, 2014 | 171.55M |
| June 30, 2014 | 151.07M |
| March 31, 2014 | 132.09M |
| December 31, 2013 | 147.29M |
| September 30, 2013 | 124.91M |
| June 30, 2013 | 112.93M |
| March 31, 2013 | 122.17M |
| December 31, 2012 | 102.05M |
| September 30, 2012 | 114.58M |
| June 30, 2012 | 123.69M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
575.97M
Minimum
Mar 2023
1.123B
Maximum
Dec 2019
785.25M
Average
795.36M
Median
Revenue (TTM) Benchmarks
| Biogen Inc | 9.608B |
| Alnylam Pharmaceuticals Inc | 2.095B |
| Biomarin Pharmaceutical Inc | 2.753B |
| Rigel Pharmaceuticals Inc | 130.30M |
| Apellis Pharmaceuticals Inc | 715.22M |